WebOnvansertib (NMS-P937, PCM-075, NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. … WebFluorescent Polarization. Fluorescence polarization (FP) immunoassay is based on the competition between mycotoxin and a mycotoxin–fluorescein tracer for a mycotoxin-specific antibody. When a fluorophore in solution is exposed to plane-polarized light at its excitation wavelength, the resulting emission is depolarized.
Onvansertib (NMS-P937) Datasheet - Selleckchem.com
WebOnvansertib (Synonyms: NMS-1286937; NMS-P937) Cat. No.: HY-15828 Purity: 99.32% Data Sheet SDS COA Handling Instructions NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM. For research use only. We do not sell to patients. Onvansertib Chemical Structure CAS No. : 1034616-18-6 Get it February 8 by … Web4 de dez. de 2024 · Optimized CarD FP assay buffer contains 20 mM Tris HCl (pH 7.9 at 37 °C), 150 mM potassium glutamate (KGlu), 10 mM MgCl 2, 0.1 mM EDTA, 0.01% Triton X-100, 5 mM DTT unless noted otherwise. flynn sister supply shop
Onvansertib (NMS-1286937) PLK1 Inhibitor MedChemExpress
WebASSAY IMPURITIES Procedure Organic Impurities (added) PERFORMANCE TESTS ADDITIONAL REQUIREMENTS Dissolution Packaging and Storage and USP Reference … WebFluorescence Polarization (FP) Fluorescence polarization (FP) is a technique that is widely used to monitor binding events in solution. It can be used to assess biomolecular … PLK1 is an oncogenic kinase that controls cell cycle and proliferation and has been preclinically validated as a cancer therapeutic target. Onvansertib (PCM-075) is a novel, orally available PLK1 inhibitor, which shows tumor growth inhibition in various types of cancer. Ver mais Brain tumors are now the leading cause of mortality from cancer in children.1 Medulloblastoma (MB), the most common malignant brain tumor in childhood, is a diverse and … Ver mais MYC-driven Group 3 medulloblastoma is an aggressive pediatric brain tumor that is refractory to intensive multimodal therapy. While specifically targeting MYC amplification has remained problematic due to the absence of … Ver mais flynn sign company